BeiGene, Ltd. (NASDAQ:BGNE) Receives $253.69 Average PT from Analysts

BeiGene, Ltd. (NASDAQ:BGNE) has earned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $253.69.

A number of analysts recently commented on BGNE shares. StockNews.com downgraded shares of BeiGene from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. TD Cowen increased their price objective on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. lifted their target price on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, October 22nd. JMP Securities began coverage on BeiGene in a report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 target price for the company. Finally, Morgan Stanley reissued an “overweight” rating and issued a $300.00 price target on shares of BeiGene in a research note on Tuesday, December 3rd.

Insider Transactions at BeiGene

In other news, CEO John Oyler sold 6,175 shares of BeiGene stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total transaction of $1,433,958.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Xiaodong Wang sold 40,468 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $190.10, for a total transaction of $7,692,966.80. The disclosure for this sale can be found here. Insiders sold 1,125,420 shares of company stock valued at $211,134,043 over the last three months. 7.43% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Baillie Gifford & Co. increased its position in BeiGene by 0.6% during the third quarter. Baillie Gifford & Co. now owns 3,705,756 shares of the company’s stock worth $831,979,000 after buying an additional 23,807 shares during the last quarter. FMR LLC lifted its holdings in BeiGene by 0.8% in the 3rd quarter. FMR LLC now owns 1,660,011 shares of the company’s stock worth $372,689,000 after purchasing an additional 12,855 shares during the last quarter. Point72 Asset Management L.P. boosted its position in BeiGene by 74.9% during the third quarter. Point72 Asset Management L.P. now owns 667,166 shares of the company’s stock worth $149,785,000 after purchasing an additional 285,784 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in BeiGene by 160.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 225,854 shares of the company’s stock valued at $50,706,000 after purchasing an additional 138,978 shares during the last quarter. Finally, TD Asset Management Inc raised its position in shares of BeiGene by 1.4% in the second quarter. TD Asset Management Inc now owns 114,378 shares of the company’s stock valued at $16,318,000 after purchasing an additional 1,599 shares during the period. Institutional investors own 48.55% of the company’s stock.

BeiGene Stock Performance

BGNE opened at $181.89 on Wednesday. The business has a 50 day moving average price of $197.08 and a two-hundred day moving average price of $188.76. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The company has a market capitalization of $17.74 billion, a price-to-earnings ratio of -22.07 and a beta of 0.57. BeiGene has a 1-year low of $126.97 and a 1-year high of $248.16.

BeiGene (NASDAQ:BGNE) last announced its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. During the same period in the prior year, the business earned $2.01 EPS. The company’s quarterly revenue was up 28.2% compared to the same quarter last year. Research analysts predict that BeiGene will post -5.64 EPS for the current fiscal year.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.